FrancophonIA/ELRC3.0 huggingface dataset:
English: Serious but uncommon infusion-related reactions include anaphylaxis (severe allergic reaction).
Estonian: Raskete, kuid harvaesinevate infusioonireaktsioonide hulka kuulub anafülaksia (raske allergiline reaktsioon).
English: The summary of the opinion of the Committee for Orphan Medicinal Products for Vimizim can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Estonian: Harvikravimite komitee arvamuse kokkuvõte Vimizimi kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
English: Patients may also be given a medicine to prevent fever.
Estonian: Patsientidele võib anda ka palavikuvastast ravimit.
English: Why is Vimizim approved?
Estonian: Miks Vimizim heaks kiideti?
English: The full EPAR and risk management plan summary for Vimizim can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst ja riskijuhtimiskava kokkuvõte Vimizimi kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: It is not intended to provide practical advice on how to use Vimizim.
Estonian: Hindamisaruandes ei anta Vimizimi kasutamise praktilisi nõuandeid.
English: Before treatment, the patients could walk on average just over 200 metres in six minutes.
Estonian: Enne ravi suutsid patsiendid käia 6 minuti jooksul keskmiselt veidi üle 200 meetri.
English: What are the risks associated with Vimizim?
Estonian: Mis riskid Vimizimiga kaasnevad?
English: Vimizim has been investigated in one main study involving 176 patients with MPS IVA, which compared Vimizim with placebo (a dummy treatment).
Estonian: Vimizimi on uuritud ühes põhiuuringus, kuhu kaasati 176 IVA-tüüpi mukopolüsahharidoosiga patsienti ning kus Vimizimi võrreldi platseeboga (näiv ravim).
English: The CHMP concluded that, following 6 months of treatment, Vimizim was shown to be effective at improving the distance patients could walk in six minutes, and this was accompanied by other beneficial effects, including improved ability to carry out daily activities.
Estonian: Inimravimite komitee leidis, et pärast 6-kuulist ravi osutus Vimizim efektiivseks, suurendades vahemaad, mille patsiendid suutsid 6 minutiga läbida, ning sellega kaasnes muid kasulikke mõjusid, sealhulgas paranenud suutlikkus igapäevatoimingute tegemisel.
English: Before receiving Vimizim, the patient should be given a medicine to prevent an allergic reaction to Vimizim.
Estonian: Enne kui patsient saab Vimizimi, tuleb talle manustada ravimit Vimizimivastase allergilise reaktsiooni ennetamiseks.
English: The medicine can only be obtained with a prescription and should be given by an appropriately trained healthcare professional.
Estonian: Vimizim on retseptiravim ja seda tohib manustada ainult asjakohase väljaõppega tervishoiutöötaja.
English: Enzyme replacement therapy provides patients with the enzyme they are lacking.
Estonian: Ensüümasendusravi annab patsientidele puuduvad ensüümid.
English: Vimizim must not be used in patients who have experienced life-threatening allergic reactions to elosulfase alfa or any of the other ingredients in Vimizim.
Estonian: Vimizimi ei tohi kasutada patsientidel, kel on olnud eluohtlikke allergilisi reaktsioone alfaelosulfaasi või Vimizimi mis tahes muu koostisaine suhtes.
English: Because the number of patients with MPS IVA is low, the disease is considered ‘rare', and Vimizim was designated an ‘orphan medicine' (a medicine used in rare diseases) on 24 July 2009.
Estonian: Et IVA-tüüpi mukopolüsahharidoosiga patsientide arv on väike ja see haigus esineb harva, nimetati Vimizim 24. juulil 2009 harvikravimiks.
English: It is used to treat patients with mucopolysaccharidosis type IVA (MPS IVA, also known as Morquio A syndrome).
Estonian: Seda kasutatakse IVA-tüüpi mukopolüsahharidoosiga (MPS IVA, tuntud ka nimetusega Morquio A sündroom) patsientide raviks.
English: Treatment with Vimizim should be supervised by a doctor experienced in MPS IVA or similar diseases.
Estonian: Ravi Vimizimiga peab jälgima arst, kellel on kogemusi IVA-tüüpi mukopolüsahharidoosi või sarnaste haiguste ravis.
English: The replacement enzyme helps to break down GAGs and stop them building up in cells, thereby improving the symptoms of MPS IVA.
Estonian: Asendusensüüm aitab lagundada glükosaminoglükaane ja peatada nende akumuleerumist rakkudes, leevendades nii IVA-tüüpi mukopolüsahharidoosi sümptomeid.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Vimizim, including the appropriate precautions to be followed by healthcare professionals and patients.
Estonian: Selle alusel lisati Vimizimi omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
English: Elosulfase alfa is produced by a method known as ‘recombinant DNA technology': it is made by cells into which a gene (DNA) has been introduced, which makes them able to produce the enzyme.
Estonian: Alfaelosulfaasi valmistatakse rekombinant-DNA-tehnika abil: seda toodavad rakud, millesse on viidud ensüümi teket võimaldav geen (DNA).
English: This is a summary of the European public assessment report (EPAR) for Vimizim.
Estonian: See on ravimi Vimizim Euroopa avaliku hindamisaruande kokkuvõte.
English: After 6 months, patients treated with the recommended dose of Vimizim could walk an extra 37 metres on average in six minutes, compared with an increase of 14 metres in patients receiving placebo.
Estonian: 6 kuu pärast suutsid Vimizimi soovitatava annusega ravitud patsiendid 6 minutiga käia keskmiselt 37 meetrit rohkem ja platseebot saanud patsiendid 14 meetrit rohkem.
English: For the full list of all side effects reported with Vimizim, see the package leaflet.
Estonian: Vimizimi kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: The main measure of effectiveness was the change in the distance patients could walk in six minutes after 6 months of treatment.
Estonian: Efektiivsuse põhinäitaja oli vahemaa, mille patsiendid suutsid pärast 6-kuulist ravi 6 minuti jooksul läbida.
English: How is Vimizim used?
Estonian: Kuidas Vimizimi kasutatakse?
English: For practical information about using Vimizim, patients should read the package leaflet or contact their doctor or pharmacist.
Estonian: Kui vajate Vimizimi kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: For more information about treatment with Vimizim, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Vimizimiga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: Vimizim is a medicine that contains the active substance elosulfase alfa.
Estonian: Vimizim on ravim, mis sisaldab toimeainena alfaelosulfaasi.
English: This disease is caused by the lack of an enzyme called N-acetylgalactosamine-6-sulfatase, which is needed to break down substances in the body called glycosaminoglycans (GAGs).
Estonian: Nimetatud haigus on tingitud organismis glükosaminoglükaanide (GAG) lagundamiseks vajaliku ensüümi N-atsetüülgalaktoosamiin-6-sulfataasi puudusest.
English: How does Vimizim work?
Estonian: Kuidas Vimizim toimib?
English: The active substance in Vimizim, elosulfase alfa, is a copy of the human enzyme N-acetylgalactosamine-6-sulfatase.
Estonian: Vimizimi toimeaine alfaelosulfaas on inimese ensüümi N-atsetüülgalaktoosamiin-6-sulfataasi koopia.
English: What benefits of Vimizim have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Vimizimi kasulikkus?
English: Vimizim is an enzyme replacement therapy.
Estonian: Vimizim on ensüümasendusravi ravim.
English: Vimizim is available as a concentrate to be made into a solution for infusion (drip) into a vein.
Estonian: Vimizimi turustatakse kontsentraadina, millest valmistatakse infusioonlahus veeni tilgutamiseks.
English: Vimizim elosulfase alfa
Estonian: Vimizim alfaelosulfaas
English: ATCvet code: QP53BX03.
Estonian: ATCvet kood: QP53BX03.
English: Plasma protein binding is high (~99%).
Estonian: Siduvus plasma proteiinidega on kõrge (~99%).
English: Bioavailability was shown to be approximately 70%.
Estonian: Nende biosaadavus on uuringute andmetel ligikaudu 70%.
English: DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 11/02/2011.
Estonian: ESMASE MÜÜGILOA VÄLJASTAMISE/MÜÜGILOA UUENDAMISE KUUPÄEV Esmase müügiloa väljastamise kuupäev: 11/02/2011.
English: Administer with food.
Estonian: Manustada koos toiduga.
English: Spinosad has been shown to be a substrate for P-glycoprotein (PgP).
Estonian: Spinosaad on osutunud P-glükoproteiini (PgP) substraadiks.
English: The recommended dosage regimen should be followed.
Estonian: Järgima peab soovitatud annustamisskeemi.
English: THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, if applicable
Estonian: MÄRGE „AINULT VETERINAARSEKS KASUTAMISEKS“ NING TINGIMUSED VÕI PIIRANGUD TARNIMISE JA KASUTAMISE OSAS, KUI NEED ON KOHALDATAVAD
English: There is no antidote available.
Estonian: Antidoodid puuduvad.
English: In the majority of cases, vomiting was transient, mild and did not require symptomatic treatment.
Estonian: Enamikul juhtudel oli oksendamine mööduv ja kergekujuline ning ei nõudnud sümptomaatilist ravi.
English: Pharmacotherapeutic group: other ectoparasiticides for systemic use.
Estonian: FARMAKOLOOGILISED OMADUSED Farmakoterapeutiline rühm: muud ektoparasititsiidid süsteemseks kasutuseks.
English: Children should not come into contact with the veterinary medicinal product.
Estonian: Lapsed ei tohiks veterinaarravimiga kokku puutuda.
English: MARKETING AUTHORISATION NUMBER(S) EU/2/10/115/016 (90 mg, 3 tablets)
Estonian: MÜÜGILOA NUMBER (NUMBRID) EU/2/10/115/016 (90 mg, 3 tabletti)
English: The veterinary medicinal product can be used as part of a treatment strategy for the control of flea allergy dermatitis (FAD).
Estonian: Veterinaarravimit tohib kasutada osana kirbuallergilise dermatiidi (FAD) raviprogrammis.
English: Interaction with other medicinal products and other forms of interaction:
Estonian: Koostoimed teiste ravimitega ja teised koostoimed:
English: In very rare cases, blindness, impaired vision and other eye disorders were observed.
Estonian: Väga harvadel juhtudel täheldati pimedust, nägemise halvenemist ja teisi silmade häireid.
English: These effects are caused primarily by activation of nicotinic acetylcholine receptors (nAChRs).
Estonian: Seda toimet põhjustab eelkõige nikotiinsete atsetüülkoliini retseptorite (nAchR) aktivatsioon.
English: If fleas reappear in the fourth week, the treatment interval can be shortened by up to 3 days in dogs.
Estonian: Kui kirbud ilmuvad uuesti neljandal nädalal, võib raviintervalli koertel kuni 3 päeva võrra lühendada.
English: The use of the product in smaller dogs and smaller cats is therefore not recommended.
Estonian: Seepärast ei ole ravimi kasutamine väiksematel koertel ja väiksematel kassidel soovitav.
English: Do not use in dogs or cats under 14 weeks of age.
Estonian: Mitte kasutada alla 14 nädala vanustel koertel ega kassidel.
English: Cardboard box containing blister, each containing 3 or 6 chewable tablets.
Estonian: Pappkarbid sisaldavad blistreid, millest igaüks sisaldab 3 kuni 6 närimistabletti.
English: Spinosad could therefore interact with other PgP-substrates (for example, digoxin, doxorubicin) and possibly enhance adverse reactions from such molecules or compromise efficacy.
Estonian: Spinosaad võib seepärast reageerida teiste PgP-substraatidega (nt digoksiin, doksorubitsiin), nende molekulide põhjustatud kõrvaltoimeid tugevdada või efektiivsust vähendada.
English: In case of adverse clinical signs, the animal should be treated symptomatically.
Estonian: Kliiniliste kõrvalnähtude korral ravida looma sümptomaatiliselt.
English: MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS
Estonian: MIINIMUMNÕUDED, MIS PEAVAD OLEMA BLISTER -VÕI RIBAPAKENDIL
English: Approximately 90% of spinosad is comprised of spinosyns A and D. Of that 90%, the ratio of spinosyn A to A+D is 0.85 when calculated as spinosyn A/spinosyn A+D.
Estonian: Ligikaudu 90% spinosaadi koostisest moodustavad spinosüünid A ja D. Selles 90% on spinosüüni A suhe spinosüünide A ja D summaga (A+D) 0,85, arvutatuna kui spinosüün A/spinosüünid A+D.
English: If the dog or cat does not accept the tablets directly they may be administered with food, or directly by opening the animal's mouth and placing the tablet onto the back of the tongue.
Estonian: Kui koer või kass ei võta tablette eraldi, võib neid manustada koos toiduga või otseselt, avades looma suu ja pannes tableti keele tagaosale.
English: The mean Tmax for spinosyns A and D ranged from 2-4 hours and the mean elimination half-life ranged from 127.5 to 162.6 hours and 101.3 to 131.9 hours respectively.
Estonian: Spinosüünide A ja D keskmine Tmax oli vahemikus 2-4 tundi ja keskmine elimineerumise poolestusaeg vastavalt vahemikus 127,5 kuni 162,6 tundi ja 101,3 kuni 131,9 tundi.
English: Fleas from pets often infest the animal's basket, bedding and regular resting areas such as carpets and soft furnishings, which should be treated in case of massive infestation and at the beginning of the treatment with a suitable insecticide and vacuumed regularly.
Estonian: Kirbud levivad lemmikloomadelt sageli loomade korvidesse, magamisvarustusse ja tavalistesse puhkekohtadesse nagu vaibad ja pehme mööbel, mida tuleb suure infestatsiooni puhul ja ravi alguses töödelda sobiva putukatõrjevahendiga ning regulaarselt tolmuimejaga puhastada.
English: Use with caution in dogs and cats with pre-existing epilepsy.
Estonian: Kasutada ettevaatusega koertel ja kassidel, kellel on esinenud epilepsiat.
English: Furthermore, a reduction of food intake was observed in females, however a significant reduction in their bodyweight was not observed.
Estonian: Emastel kassidel täheldati ka söödud toidu koguse vähenemist, kuigi ei täheldatud olulist kehamassi langust.
English: Regular monthly treatments with Comfortis break the fleas' life cycle and may be needed to control the flea population in contaminated households.
Estonian: Regulaarne igakuine ravi Comfortisega katkestab kirpude elutsükli ning võib osutuda vajalikuks, et kirpude populatsiooni nakatatud majapidamises kontrolli all hoida.
English: The recommended dosage regimen should be followed (see section 4.10 for information regarding overdose).
Estonian: Järgida tuleb soovitatud annustamisskeemi (informatsiooni saamiseks üleannustamise kohta vt punkt
English: However there was no evidence in the clinical observations and clinical chemistry parameters that indicated any loss in organ function.
Estonian: Siiski ei leitud kliiniliste vaatluste ja kliinilise keemia parameetrite alusel tõendeid, mis oleks näidanud organi funktsiooni kadu.
English: Insecticidal activity against new infestations persists for up to 4 weeks.
Estonian: Insektitsiidne toime uute infestatsioonide vastu püsib kuni 4 nädalat.
English: MANUFACTURER'S BATCH NUMBER Lot
Estonian: TOOTJAPOOLNE PARTII NUMBER Partii nr
English: Other commonly observed adverse reactions in cats were diarrhoea and anorexia.
Estonian: Muud sageli ilmnenud kõrvaltoimed kassidel olid kõhulahtisus ja anoreksia.
English: The veterinary medicinal product may safely be given at monthly intervals at the recommended dose.
Estonian: Veterinaarravimit võib ohutult anda soovitatud annuses kuuajaliste intervallidega.
English: It does not interact with known binding sites of other nicotinic or GABAergic insecticides such as neonicotinides (imidacloprid or nitenpyram), fiproles (fipronil), milbemycins, avermectins (e.g. selamectin) or cyclodienes, but through a novel insecticidal mechanism.
Estonian: Ta ei reageeri teadaolevate teiste nikotiinsete või GABAergiliste insektitsiidide nagu neonikotiniidid (imidaklopriid või nitenpyram), fenüülpürasoolid (fiproniil), milbemütsiinid, avermektiinid (nt selamektiin) või tsüklodieenid sidumissaitidega, vaid tema puhul on tegemist uudse insektitsiidse toimemehhanismiga.
English: Phospholipidosis (vacuolation of lymphoid tissue) also occurred; although this was not related to clinical signs in dogs treated up to 6 months.
Estonian: Samuti esines fosfolipidoosi (vakuoolide teket lümfikoes), kuigi see ei olnud seotud kliiniliste sümptomitega koertel, keda raviti kuni 6 kuud.
English: Dogs Dogs and cats
Estonian: Koer Koer ja kass
English: Blisters
Estonian: Blisterid
English: All dogs and cats within the household should be treated.
Estonian: Ravida tuleb kõiki majapidamises olevaid koeri ja kasse.
English: The product starts killing fleas 30 minutes after administration; 100% of fleas are dead/moribund within 4 hours post-treatment in dogs, and in cats within 24 hours.
Estonian: Ravimi toime kirpude vastu algab 30 minutit pärast manustamist; koertel 4 tunni möödudes manustamisest ja kassidel 24 tunni jooksul on surnud/suremas 100% kirpudest.
English: Post marketing reports, following the concomitant use of Comfortis with ‘off label' high dose ivermectin indicate that dogs have experienced trembling/twitching, salivation/drooling, seizures, ataxia, mydriasis, blindness and disorientation.
Estonian: Turundusjärgsed uuringud, kus käsitleti Comfortise kasutamist koos suures annuses „off label“ ivermektiiniga, on näidanud, et koertel esines värisemist/tõmblemist, süljevoolust/ilastamist, krampe, ataksiat, müdriaasi, pimedust ja orientatsioonikaotust.
English: PACKAGE SIZE 3 tablets
Estonian: PAKENDI SUURUS(ED) 3 tabletti
English: In cats, the full 4 week gap between treatments should be maintained, even if fleas reappear (due to an occasional slightly reduced persistent efficacy) before the end of the 4 weeks.
Estonian: Kassidel peab jätma ravimi andmise vahel kindlasti 4-nädalase vahe, isegi kui kirbud ilmuvad uuesti (tingituna veidi vähenenud püsiefektiivsusest) enne 4 nädala lõppu.
English: The incidence of vomiting observed after the first and second treatments was higher (8%) in dogs dosed at the upper end of the dose band.
Estonian: Vaatlustes täheldatud oksendamise määr pärast esimest ja teist ravi oli kõrgem (8%) koertel, kelle annuse suurus oli annusevahemiku ülempiiril.
English: In adult cats, the AUC increased over 3 consecutive months of dosing with 75 mg spinosad/kg bodyweight, after which steady state was achieved; however, no clinical impact occurred as a result of this.
Estonian: Täiskasvanud kassidel suurenes AUC kolme järjestikuse annustamiskuu jooksul pärast 75 mg spinosaadi kehamassi 1 kg kohta manustamist, pärast mida saavutati tasakaalukontsentratsioon, siiski ei tulenenud sellest kliinilist toimet.
English: If vomiting occurs within an hour of administration and the tablet is visible, re-dose the animal with another full dose to ensure maximum effectiveness of the product.
Estonian: Kui tunni jooksul manustamisest tekib oksendamine ja tablett on okses näha, tuleb anda loomale uus täielik annus, et tagada ravimi maksimaalne efektiivsus.
English: Bioavailability was shown to be approximately 100%, with maximum plasma concentrations attained approximately 4-12 hours post treatment, and with half-lives of spinosyn A and spinosyn D ranging between 5 days and 20 days in cats dosed at 50-100 mg spinosad/kg bodyweight.
Estonian: Nende biosaadavus on uuringute andmetel umbes 100%, kusjuures maksimaalne plasmakontsentratsioon saavutati umbes 412 tundi pärast ravi ning spinosüünide A ja D poolväärtusajad olid kassidel, kellele annustati 50100 mg spinosaadi kehamassi 1 kg kohta, vahemikus 5 kuni 20 päeva.
English: SPECIAL STORAGE CONDITIONS Keep the blister in the outer carton.
Estonian: SÄILITAMISE ERITINGIMUSED Hoida blisterpakend välispakendis.
English: Treatment and prevention of flea infestations (Ctenocephalides felis).
Estonian: Kirpude (Ctenocephalides felis) infestatsiooni ravi ja ennetus.
English: 6.5 Nature and composition of immediate packaging Clear PCTFE/PE/PVC blister sealed with aluminium foil containing 3 or 6 chewable tablets in cardboard box.
Estonian: Pappkarbid, mis sisaldavad läbipaistvaid, alumiiniumfooliumiga õhukindlalt suletud PCTFE/PE/PVC blisterpakendeid, mis sisaldavad 3 või 6 närimistabletti.
English: Therefore, it is recommended to treat dogs with food as this maximises the opportunity for fleas to ingest lethal amounts of spinosad.
Estonian: Seepärast on soovitav anda ravimit koertele koos toiduga, sest see viib maksimumini võimaluse, et kirbud saavad surmava koguse spinosaadi.
English: Keep the blister in the outer carton to protect from light.
Estonian: Valguse eest kaitsmiseks hoida blister välispakendis.
English: In cats, the full 4 week gap between treatments should be maintained, even if fleas reappear before the end of the 4 weeks.
Estonian: Kassidel peab jätma ravimi andmise vahel kindlasti 4-nädalase vahe, isegi kui kirbud ilmuvad uuesti enne 4 nädala lõppu.
English: Comfortis tablets are chewable and palatable for dogs.
Estonian: Comfortise tabletid on koertele näritavad ja hea maitsega.
English: The preventive effect against re-infestations is a result of the activity against adult fleas and the reduction in their production of eggs.
Estonian: Ennetav toime uute infestatsioonide vastu põhineb täiskasvanud kirpude hävitamisel ja tingude tekke vähendamisel.
English: Accurate dosing is not possible in dogs weighing less than 1.3 kg and in cats weighing less than 1.2 kg.
Estonian: Koertele, kes kaaluvad alla 1,3 kg, ja kassidele, kes kaaluvad vähem kui 1,2 kg, ei ole võimalik ravimit õigesti annustada.
English: The consistency of this figure in pharmacokinetic and other studies indicates comparability in the absorption, metabolism and elimination of the two major spinosyns.
Estonian: See suhtarv on farmokokineetiliste ja teiste uuringute järgi samasugune ka siis, kui kõne all on nende kahe peamise spinosüüni imendumine, ainevahetus ja elimineerumine.
English: The tablets are speckled tan to brown, round, flat and chewable.
Estonian: Tabletid on tähnilised, kollakaspruunid kuni pruunid, ümmargused, lamedad ja näritavad.
English: At doses of approximately 2.5 times the recommended dose, spinosad caused vomiting in the vast majority of dogs.
Estonian: Annuste puhul, mis ületasid soovitatud annust ligikaudu 2,5 korda, kutsus spinosaad esile oksendamise suuremal osal koertest.
English: Spinosad comprises spinosyn A and spinosyn D. The insecticidal activity of spinosad is characterised by nervous excitation leading to muscle contractions and tremors, prostration, paralysis and rapid death of the flea.
Estonian: Spinosaad sisaldab spinosüüni A ja spinosüüni D. Spinosaadi insektitsiidset toimet iseloomustab erutuse tekitamine kirbu närvisüsteemis, mis viib lihasekontraktsioonide ja treemorini, prostratsioonini, halvatuseni ja kirbu kiire surmani.
English: In dogs, spinosad is excreted in the colostrum and milk of lactating bitches and it is therefore assumed that spinosad is excreted in the colostrum and milk of lactating queens.
Estonian: Koertel eritub spinosaad laktatsiooniperioodil emaste koerte ternespiima ja piima ning seetõttu eeldatakse, et spinosaad eritub laktatsiooniperioodil emaste kasside ternespiima ja piima.
English: Spinosad therefore has a different mode of action to other flea control or insect control products.
Estonian: Seega erineb spinosaadi toimemehhanism teiste kirbu- ja putukatõrjevahendite omast.
English: INDICATION(S) For the treatment and prevention of flea infestations.
Estonian: NÄIDUSTUS(ED) Kirbuinfestatsioonide raviks ja ennetuseks.
English: Comfortis 1620 mg chewable tablets for dogs spinosad
Estonian: Comfortis 1620 mg närimistabletid koertele spinosaad
English: AUC and Cmax values were higher in fed than fasted dogs and increased approximately linearly with increasing dose-rates over the intended therapeutic dose range.
Estonian: AUC ja Cmax väärtused olid kõrgemad koertel, kes said ravimit täis kõhuga (võrreldes koertega, kes said ravimit tühja kõhuga) ning suurenesid ligikaudu lineaarselt koos annusemäärade suurenemisega kogu kavandatud terapeutilise annusepiirkonna raames.